---
title: "vTv Therap (VTVT.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VTVT.US/norm.md"
symbol: "VTVT.US"
name: "vTv Therap"
parent: "https://longbridge.com/en/quote/VTVT.US.md"
datetime: "2026-05-21T02:57:49.618Z"
locales:
  - [en](https://longbridge.com/en/quote/VTVT.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VTVT.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VTVT.US/norm.md)
---

# vTv Therap (VTVT.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | 1.65 | -0.5752 | -1.08 | -0.9179 | -0.7735 |
| ROE | 125.05% | -42.31% | -94.92% | -452.80% | -202.48% |
| Revenue | 36.84M | - | - | - | - |
| Net income | 24.13M | -7.14M | -8.70M | -6.05M | -5.09M |
| Operating income | 23.26M | -7.88M | -10.70M | -7.72M | -6.50M |
| Gross margin | 75.63% | - | - | - | - |
| Net margin | 65.51% | - | - | - | - |
| Profit quality | 254.13% | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 98.81M | 89.90M | 99.49M | 26.45M | 32.03M |
| Leverage | 1.10 | 1.40 | 1.41 | 11.00 | 3.60 |
| BVPS | 7.25 | 5.19 | 5.68 | 0.4193 | 1.20 |
| Turnover | 0.5631 | - | 0.0002 | 0.0005 | 0.0004 |
| Cash & STI | 98.09M | 88.93M | 98.50M | 25.92M | 31.06M |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | 38000.00 | 74000.00 | 111000.00 |
| Net debt | -98.09M | -88.93M | -98.14M | -25.84M | -30.93M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | 9.15M | -9.25M | -5.22M | -5.09M | -5.69M |
| Investing CF | - | - | - | - | - |
| Financing CF | - | -321000.00 | 77.80M | -42000.00 | - |
| Free CF | 16.41M | -7.07M | -1.59M | -2.46M | -3.57M |
| OCF coverage | - | -2820.43% | -8159.38% | - | - |
| Repaid & issued | - | 0.0000 | 392000.00 | - | - |
| CapEx | - | - | - | - | - |